Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage
Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance
(MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require
treatment. The primary aim of the study is to determine if the Omega 3 supplementation will
help prevent or delay progression of the disease to a stage that requires treatment.